Funds › Knott David M Jr
Knott David M Jr
13F for Q3 2026, filed Nov 12, 2026. 80 positions worth $182.8M.Managers with more than $100 million in US-listed stocks list their holdings each quarter, within 45 days of quarter end. Long positions only: no short sales or cash.
Latest report
Q3 2026
filed Nov 12, 2026
Reported value
$182.8M
−$6.3M (3.4%) vs Q2 2026
Positions
80
84 in Q2 2026
Top 10 share
66.7%
of reported value
CheckedEach line's price per share is checked against other managers' reports of the same stock. Unit mix-ups are corrected. Reports no fix can rescue are left out.
Clean
prices match other managers' reports
Ask your AI about this
Connect Claude, ChatGPT, Gemini or Grok (Microsoft 365 Copilot coming soon) to 13F.ai and ask in plain English. Copy a question to get started:
Using 13F.ai, what are the biggest new, added, trimmed and exited positions of Knott David M Jr in the latest 13F quarter?
Using 13F.ai, how has Knott David M Jr's portfolio concentration changed over the last four quarters?
Using 13F.ai, which of Knott David M Jr's top holdings have also been bought by insiders recently?
Connect your AI · Plans and the 7-day free trial (card required)
Holdings, Q3 2026
Largest first. Common shares only; puts and calls are under All positions.
| # | The fund's own figures at the end of the quarter. A report can be up to 45 days old when it is filed. Options and bonds are not counted here. | Filing | ||||
|---|---|---|---|---|---|---|
| 1 | GOOG Alphabet Inc. Class C | 91,420 | $31.2M | 17.0% | Unchanged | 13F ↗ |
| 2 | APO Apollo Global Management, Inc. | 225,000 | $26.1M | 14.3% | Unchanged | 13F ↗ |
| 3 | IOVA Iovance Biotherapeutics, Inc. | 1.17M | $17.3M | 9.4% | -27.2% | 13F ↗ |
| 4 | XERS Xeris Biopharma Holdings, Inc. | 1.00M | $9.6M | 5.2% | -5.4% | 13F ↗ |
| 5 | SNDX Syndax Pharmaceuticals, Inc. | 428,294 | $8.1M | 4.4% | -2.0% | 13F ↗ |
| 6 | TVTX Travere Therapeutics, Inc. | 129,967 | $7.7M | 4.2% | -11.8% | 13F ↗ |
| 7 | BBIO BridgeBio Pharma, Inc. | 100,000 | $6.6M | 3.6% | +7.7% | 13F ↗ |
| 8 | JPM JPMorgan Chase & Co. | 17,409 | $5.8M | 3.2% | -3.8% | 13F ↗ |
| 9 | LPL Financial Holdings Inc | 16,500 | $5.0M | 2.8% | Unchanged | 13F ↗ |
| 10 | Janus Detroit Str Tr Hendrson Aaa Cl | 93,528 | $4.7M | 2.6% | Unchanged | 13F ↗ |
| 11 | ALKS Alkermes plc | 114,459 | $4.6M | 2.5% | -6.0% | 13F ↗ |
| 12 | PTGX Protagonist Therapeutics, Inc. | 32,723 | $4.6M | 2.5% | -48.1% | 13F ↗ |
| 13 | Cybin Inc | 370,000 | $4.5M | 2.5% | Unchanged | 13F ↗ |
| 14 | COGT Cogent Biosciences, Inc. | 136,081 | $4.4M | 2.4% | +22.5% | 13F ↗ |
| 15 | VRDN Viridian Therapeutics, Inc. | 191,000 | $3.9M | 2.2% | +5.5% | 13F ↗ |
| 16 | TGTX TG Therapeutics, Inc. | 59,839 | $3.3M | 1.8% | -10.5% | 13F ↗ |
| 17 | RCUS Arcus Biosciences, Inc. | 100,241 | $2.6M | 1.4% | +23.4% | 13F ↗ |
| 18 | MDGL Madrigal Pharmaceuticals, Inc. | 3,600 | $1.8M | 1.0% | +20.0% | 13F ↗ |
| 19 | RLMD Relmada Therapeutics, Inc. | 480,000 | $1.8M | 1.0% | +6.4% | 13F ↗ |
| 20 | Spdr Series Trust St Str Sp Biot | 11,000 | $1.7M | 0.9% | -26.7% | 13F ↗ |
| 21 | AB Alliancebernstein Holding L.P. · Units | 48,000 | $1.7M | 0.9% | Unchanged | 13F ↗ |
| 22 | AGIO Agios Pharmaceuticals, Inc. | 49,058 | $1.6M | 0.9% | -48.4% | 13F ↗ |
| 23 | OBIO Orchestra BioMed Holdings, Inc. | 253,651 | $1.6M | 0.9% | Unchanged | 13F ↗ |
| 24 | CGEM Cullinan Therapeutics, Inc. | 95,369 | $1.5M | 0.8% | +37.9% | 13F ↗ |
| 25 | CDNA CareDx, Inc. | 22,165 | $1.4M | 0.8% | +62.6% | 13F ↗ |
| 26 | ELVN Enliven Therapeutics, Inc. | 28,904 | $1.3M | 0.7% | +367% | 13F ↗ |
| 27 | SPRB Spruce Biosciences, Inc. | 26,085 | $1.3M | 0.7% | +30.4% | 13F ↗ |
| 28 | Series Portfolios Tr Eldridge Bbb B | 47,807 | $1.3M | 0.7% | Unchanged | 13F ↗ |
| 29 | DCGO DocGo Inc. | 2.67M | $1.1M | 0.6% | Unchanged | 13F ↗ |
| 30 | PFE Pfizer, Inc. | 32,337 | $922.3K | 0.5% | Unchanged | 13F ↗ |
| 31 | ORKA Oruka Therapeutics, Inc. | 11,000 | $916.2K | 0.5% | New | 13F ↗ |
| 32 | COLL Collegium Pharmaceutical, Inc. | 39,000 | $851.0K | 0.5% | New | 13F ↗ |
| 33 | DYN Dyne Therapeutics, Inc. | 52,000 | $837.7K | 0.5% | New | 13F ↗ |
| 34 | AAPL Apple Inc. | 2,494 | $830.6K | 0.5% | Unchanged | 13F ↗ |
| 35 | MSFT Microsoft Corporation | 1,600 | $820.6K | 0.4% | Unchanged | 13F ↗ |
| 36 | JNJ Johnson & Johnson | 2,922 | $773.6K | 0.4% | -40.6% | 13F ↗ |
| 37 | RZLT Rezolute, Inc. | 159,638 | $660.9K | 0.4% | -56.9% | 13F ↗ |
| 38 | CNQ Canadian Natural Resources Limited | 13,918 | $655.1K | 0.4% | -17.2% | 13F ↗ |
| 39 | LBRX LB Pharmaceuticals Inc | 17,065 | $655.0K | 0.4% | +31.6% | 13F ↗ |
| 40 | iShares Tr Ishares Biotech | 2,500 | $526.3K | 0.3% | -54.5% | 13F ↗ |
| 41 | SLDB Solid Biosciences Inc. | 71,129 | $514.3K | 0.3% | +26.5% | 13F ↗ |
| 42 | Dupont De Nemours Inc | 3,767 | $489.3K | 0.3% | New | 13F ↗ |
| 43 | IBM International Business Machines Corporation | 2,142 | $471.1K | 0.3% | Unchanged | 13F ↗ |
| 44 | CNTB Connect Biopharma Holdings Limited | 419,866 | $461.9K | 0.3% | -5.6% | 13F ↗ |
| 45 | BIIB Biogen Inc. | 2,000 | $451.8K | 0.2% | -50.0% | 13F ↗ |
| 46 | EWTX Edgewise Therapeutics, Inc. | 10,502 | $426.4K | 0.2% | New | 13F ↗ |
| 47 | PTHS Pelthos Therapeutics Inc. | 17,644 | $370.7K | 0.2% | -20.1% | 13F ↗ |
| 48 | NVDA NVIDIA Corporation | 1,280 | $292.3K | 0.2% | Unchanged | 13F ↗ |
| 49 | RHP Ryman Hospitality Properties, Inc. | 2,400 | $286.9K | 0.2% | Unchanged | 13F ↗ |
| 50 | INSM Insmed Incorporated · Com Par $.01 | 2,253 | $257.2K | 0.1% | -47.0% | 13F ↗ |
Showing the top 50 of 80 positions. Premium lists every position, plus puts and calls.
Changes since Q2 2026
8 new, 12 added to, 18 trimmed, 12 exited, 42 unchanged. By estimated dollars.
New positions (8)
| ORKA Oruka Therapeutics, Inc. | 11,000 | New | $916.2K |
| COLL Collegium Pharmaceutical, Inc. | 39,000 | New | $851.0K |
| DYN Dyne Therapeutics, Inc. | 52,000 | New | $837.7K |
| Dupont De Nemours Inc | 3,767 | New | $489.3K |
| EWTX Edgewise Therapeutics, Inc. | 10,502 | New | $426.4K |
| MLYS Mineralys Therapeutics, Inc. | 10,000 | New | $251.3K |
| NVCT Nuvectis Pharma, Inc. | 6,777 | New | $143.1K |
| ABVX Abivax SA · ADR | 1,000 | New | $99.0K |
Added to (12)
| ELVN Enliven Therapeutics, Inc. | 28,904 | +367% | $1.0M |
| COGT Cogent Biosciences, Inc. | 136,081 | +22.5% | $800.5K |
| CDNA CareDx, Inc. | 22,165 | +62.6% | $554.8K |
| RCUS Arcus Biosciences, Inc. | 100,241 | +23.4% | $490.8K |
| BBIO BridgeBio Pharma, Inc. | 100,000 | +7.7% | $470.5K |
| CGEM Cullinan Therapeutics, Inc. | 95,369 | +37.9% | $402.0K |
| MDGL Madrigal Pharmaceuticals, Inc. | 3,600 | +20.0% | $302.4K |
| SPRB Spruce Biosciences, Inc. | 26,085 | +30.4% | $295.6K |
| VRDN Viridian Therapeutics, Inc. | 191,000 | +5.5% | $205.9K |
| LBRX LB Pharmaceuticals Inc | 17,065 | +31.6% | $157.4K |
Trimmed (18)
| IOVA Iovance Biotherapeutics, Inc. | 1.17M | -27.2% | -$6.4M |
| PTGX Protagonist Therapeutics, Inc. | 32,723 | -48.1% | -$4.3M |
| AGIO Agios Pharmaceuticals, Inc. | 49,058 | -48.4% | -$1.5M |
| TVTX Travere Therapeutics, Inc. | 129,967 | -11.8% | -$1.0M |
| RZLT Rezolute, Inc. | 159,638 | -56.9% | -$870.9K |
| iShares Tr Ishares Biotech | 2,500 | -54.5% | -$631.6K |
| Spdr Series Trust St Str Sp Biot | 11,000 | -26.7% | -$630.7K |
| XERS Xeris Biopharma Holdings, Inc. | 1.00M | -5.4% | -$545.9K |
| JNJ Johnson & Johnson | 2,922 | -40.6% | -$529.5K |
| BIIB Biogen Inc. | 2,000 | -50.0% | -$451.8K |
Exited (12)
| CLST Catalyst Bancorp, Inc. | 114,000 | Exited | -$3.6M |
| ATRC AtriCure, Inc. | 51,400 | Exited | -$1.4M |
| ARDX Ardelyx, Inc. | 263,168 | Exited | -$1.3M |
| RARE Ultragenyx Pharmaceutical Inc. | 38,069 | Exited | -$1.3M |
| VERA Vera Therapeutics, Inc. | 26,000 | Exited | -$1.1M |
| VSTM Verastem, Inc. | 155,000 | Exited | -$592.1K |
| KURA Kura Oncology, Inc. | 52,767 | Exited | -$578.9K |
| DuPont de Nemours, Inc | 3,767 | Exited | -$511.0K |
| QTTB Q32 Bio Inc. | 30,412 | Exited | -$387.4K |
| BSX Boston Scientific Corporation | 6,000 | Exited | -$256.1K |
The 10 largest of each, by estimated dollars: shares changed times the later report's price. Index tracking, splits and mergers move positions too.
All positions
Search, sort and filter every position, with puts and calls on their own tab. Premium plan.
Every position, puts and calls. Part of Premium.
Compare two quarters
Pick any two quarters: what is new, added to, trimmed or exited. Premium plan.
Any two quarters side by side. Part of Premium.
Reported value by quarter
Value and number of positions at the end of each quarter.
Loading…
Largest positions in earlier quarters
Pick a quarter to see what the fund's biggest positions were then.
Loading…
Ten largest positions
By value, Q3 2026.
Filings
| Filing | ||||||
|---|---|---|---|---|---|---|
| Q3 2026 | Nov 12, 2026 | 13F-HR | 80 | $182.8M | Current | SEC ↗ |
| Q2 2026 | Aug 12, 2026 | 13F-HR | 84 | $189.2M | Current | SEC ↗ |
| Q1 2026 | May 14, 2026 | 13F-HR | 85 | $168.0M | Current | SEC ↗ |
| Q4 2025 | Feb 12, 2026 | 13F-HR | 87 | $215.9M | Current | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | 13F-HR | 88 | $248.0M | Current | SEC ↗ |
| Q2 2025 | Aug 11, 2025 | 13F-HR | 85 | $220.6M | Current | SEC ↗ |
| Q1 2025 | May 12, 2025 | 13F-HR | 84 | $212.0M | Current | SEC ↗ |
Most recent first, up to 80. An amendment can replace a report or add holdings to it. All 13F filings
Information, not investment advice. Values are the fund's own figures at quarter end; a report can be up to 45 days old when filed. Disclaimer